MX390941B - Combinacion farmaceutica que comprende ponesimod. - Google Patents

Combinacion farmaceutica que comprende ponesimod.

Info

Publication number
MX390941B
MX390941B MX2019010874A MX2019010874A MX390941B MX 390941 B MX390941 B MX 390941B MX 2019010874 A MX2019010874 A MX 2019010874A MX 2019010874 A MX2019010874 A MX 2019010874A MX 390941 B MX390941 B MX 390941B
Authority
MX
Mexico
Prior art keywords
ponesimod
pharmaceutical combination
combination including
active ingredient
teriflunomide
Prior art date
Application number
MX2019010874A
Other languages
English (en)
Spanish (es)
Other versions
MX2019010874A (es
Inventor
Laetitia Pouzol
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2019010874A publication Critical patent/MX2019010874A/es
Publication of MX390941B publication Critical patent/MX390941B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
MX2019010874A 2017-03-14 2018-03-13 Combinacion farmaceutica que comprende ponesimod. MX390941B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017055994 2017-03-14
PCT/EP2018/056185 WO2018167030A1 (en) 2017-03-14 2018-03-13 Pharmaceutical combination comprising ponesimod

Publications (2)

Publication Number Publication Date
MX2019010874A MX2019010874A (es) 2019-12-11
MX390941B true MX390941B (es) 2025-03-21

Family

ID=61655772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010874A MX390941B (es) 2017-03-14 2018-03-13 Combinacion farmaceutica que comprende ponesimod.

Country Status (24)

Country Link
US (3) US11723896B2 (https=)
EP (1) EP3595657A1 (https=)
JP (3) JP7281406B2 (https=)
KR (1) KR102574562B1 (https=)
CN (1) CN110381942B (https=)
AU (2) AU2018233109B2 (https=)
BR (1) BR112019018894A2 (https=)
CA (1) CA3056301C (https=)
CL (1) CL2019002525A1 (https=)
CO (1) CO2019008510A2 (https=)
CR (1) CR20190464A (https=)
DO (1) DOP2019000257A (https=)
EA (1) EA201992117A1 (https=)
EC (1) ECSP19073317A (https=)
IL (1) IL269239B2 (https=)
JO (1) JOP20190207A1 (https=)
MA (1) MA49822A (https=)
MX (1) MX390941B (https=)
NI (1) NI201900092A (https=)
PE (1) PE20191489A1 (https=)
PH (1) PH12019502110A1 (https=)
SG (1) SG11201907308UA (https=)
UA (1) UA125756C2 (https=)
WO (1) WO2018167030A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
CA2400290A1 (en) * 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
EP1381356B1 (en) 2001-04-05 2008-05-28 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US6894184B2 (en) 2003-03-18 2005-05-17 Aventis Pharma Deutschland Gmbh Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
PT1689726E (pt) 2003-11-21 2010-12-09 Actelion Pharmaceuticals Ltd Derivados de 5-(benz-(z)-ilideno)-tiazolidin-4-ona como agentes imunossupressores
CA2584655A1 (en) 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
DE102006017896A1 (de) 2006-04-13 2007-10-25 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Leflunomid enthaltende pharmazeutische Zusammensetzungen
US8263780B2 (en) 2006-11-23 2012-09-11 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
HUE033168T2 (en) 2008-03-17 2017-11-28 Actelion Pharmaceuticals Ltd Dosage regimen for selective SIP1 receptor agonist
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
US20120172427A1 (en) 2009-09-18 2012-07-05 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
EP2598126A2 (en) 2010-07-30 2013-06-05 Saint Louis University Methods of treating pain
WO2012018704A1 (en) 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
MX350891B (es) 2012-08-17 2017-09-22 Actelion Pharmaceuticals Ltd Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso.
WO2016079687A1 (en) 2014-11-18 2016-05-26 Lupin Limited Oral pharmaceutical composition of teriflunomide
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
CA2987798A1 (en) 2015-06-18 2016-12-22 Matinas Biopharma Nanotechnologies, Inc. Compositions and methods for treating inflammatory disease or conditions
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Also Published As

Publication number Publication date
JP2024096962A (ja) 2024-07-17
JOP20190207A1 (ar) 2019-09-10
PE20191489A1 (es) 2019-10-21
AU2023274118B2 (en) 2024-12-12
US12527772B2 (en) 2026-01-20
JP2023030091A (ja) 2023-03-07
JP7281406B2 (ja) 2023-05-25
PH12019502110A1 (en) 2020-03-16
IL269239B2 (en) 2023-07-01
CL2019002525A1 (es) 2020-02-07
WO2018167030A1 (en) 2018-09-20
AU2018233109A1 (en) 2019-08-22
EP3595657A1 (en) 2020-01-22
CN110381942A (zh) 2019-10-25
MX2019010874A (es) 2019-12-11
ECSP19073317A (es) 2019-11-30
US20200069655A1 (en) 2020-03-05
US20260108501A1 (en) 2026-04-23
AU2018233109B2 (en) 2023-09-28
CA3056301C (en) 2024-10-01
IL269239A (en) 2019-11-28
AU2023274118A1 (en) 2023-12-21
EA201992117A1 (ru) 2020-02-17
DOP2019000257A (es) 2020-09-15
KR20190122716A (ko) 2019-10-30
UA125756C2 (uk) 2022-06-01
CN110381942B (zh) 2022-12-27
CA3056301A1 (en) 2018-09-20
IL269239B1 (en) 2023-03-01
MA49822A (fr) 2020-06-17
US20240139161A1 (en) 2024-05-02
BR112019018894A2 (pt) 2020-04-14
US11723896B2 (en) 2023-08-15
NI201900092A (es) 2020-03-11
JP2020510045A (ja) 2020-04-02
SG11201907308UA (en) 2019-09-27
KR102574562B1 (ko) 2023-09-04
CR20190464A (es) 2019-11-26
CO2019008510A2 (es) 2019-10-21

Similar Documents

Publication Publication Date Title
PH12019502110A1 (en) Pharmaceutical combination comprising ponesimod
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
ECSP19057403A (es) Usos terapéuticos de un polvo de insectos
MX2019007571A (es) Polimorfos.
MX391533B (es) Composiciones de saponinas y extractos vegetales.
MX2018009861A (es) Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.
MX383931B (es) Compuestos de aza-piridona y usos de estos.
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
JOP20200155B1 (ar) صور متعددة الأشكال
NZ769658A (en) Anti-influenza virus agent for suppressing aggravation of influenza
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
IL285765A (en) Therapeutic uses of dulaglutide
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
MX376853B (es) Odorante osmanthus.
DOP2019000015A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CO2019007261A2 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX378539B (es) Analagos de apelina ciclicos.
BR112019024634A2 (pt) Materiais emm-23 e processos e usos dos mesmos
EA201990162A1 (ru) Фармацевтические композиции
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
PY1976477A (es) Composición de oxima de ciclohexanodiona estabilizada
UA118382C2 (uk) Пероральна дозована форма ізосорбіду динітрату
UA120448U (uk) Фунгіцидна композиція
BR112019001976A2 (pt) inibidores da diacilglicerol aciltransferase 2
UA112035C2 (uk) 2-ізопропіл-5-метилциклогексил-4-амінобутирату гідрохлорид, що проявляє протисудомну та седативну активність